A few months ago in Barcelona, at the annual conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), thousands of participants from dozens of countries convened for Patient Community Day 2025 (PCD). This annual event brings together researchers focused on multiple sclerosis (MS) and associated demyelinating diseases, alongside people living with…
Category: Multiple Sclerosis Research
Is this one to Get ProfGs saliva going?
Tweet ProfG is on his crusade to target EBV….There are many ways to do this and one route is anti-virals and this is one example….Sounds interesting. Brincidofovir (BCV) is a broad-spectrum anti-viral agent and lipid-conjugate of cidofovir. The intracellular active form of BCV is known as CDV-PP (cidofovir diphosphate) and inhibits viral replication. I guess…
The methods for a failed trial
Tweet This a paper on the methods behind the remyelination trial that has been completed and preliminary results reported….so I am not really sure what the value is….surely one could wait and give the trial design and the results. These types of papers help you get the idea out, profK is busy doing ChariotMS and…
FDA gives tentative approval to generic Siponimod tablets for MS
The U.S. Food and Drug Administration (FDA) has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent (siponimod), to treat people with relapsing forms of multiple sclerosis (MS). According to a company press release, the therapy is indicated for use in adults with clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS). Similar…
$1M grant funds study to prevent falls in older adults with MS
A Georgia State University researcher won a $1 million U.S. Department of Veterans Affairs (VA) grant to study whether a program combining cognitive training with exercise can help prevent falls in older adults with multiple sclerosis (MS). “Falls are so common — and frightening — in older adults,” Katherine Hsieh, PhD, an assistant professor of…
CD20-depleters know one know them all?
Tweet The answer to the question above is no, but they all deplete B cells…this study looks at T and B cells after depletion with ublituximab and T cells drop transiently naive B cells show rapid and long term depletion. The depletion reproduced from paper below for CD8 T cells (left) AND B CELLS under…
Ocrelizumab inhibits MS by microbiota
Tweet This study examines changes in the gut bacteria after ocrelizumab….it changes and MS is inhibited is it cause or effect..it is hard to prove Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome. Coufal S, Zakostelska ZJ, Thon T, Roubalova R, Kadleckova D, Salakova M, Tachezy R, Hrncir T, Kverka M,…
Motivational Monday
Happy Monday, y’all! I hope you enjoyed your weekend and that you were able to do something that brought you joy. My weekend was spent reading and doing a few things around our house. Considering I have read 20 books so far this year, I had to reorganize my bookshelf because it was cluttered with…
Study: Eating a gluten-free diet may reduce MS disability for women
A six-month gluten-free diet significantly eased disability and supported a healthier body composition in women with relapsing-remitting multiple sclerosis (RRMS), a new small study found. The findings support growing evidence linking the gut-brain axis and metabolic inflammation to MS, and suggest that a gluten-free diet may be a promising dietary intervention for people with multiple sclerosis (MS). About…
Don’t Miss the Deadline for MSAA’s 2026 Art Showcase!
Every year, the Multiple Sclerosis Association of America (MSAA) highlights the artistic talents of the MS community in our award-winning virtual Art Showcase. We have received many wonderful submissions from individuals with MS across the country and are delighted to … Continue reading → Source: blog.mymsaa.org